Towa Pharmaceutical Co., Ltd. (TWAPF)
| Market Cap | 1.15B +16.9% |
| Revenue (ttm) | 1.72B +6.8% |
| Net Income | 50.87M -48.3% |
| EPS | 1.03 -48.3% |
| Shares Out | n/a |
| PE Ratio | 22.56 |
| Forward PE | n/a |
| Dividend | 0.25 (0.97%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 100 |
| Open | 25.98 |
| Previous Close | n/a |
| Day's Range | 25.98 - 25.98 |
| 52-Week Range | 25.71 - 26.00 |
| Beta | -0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Towa Pharmaceutical
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of... [Read more]
Financial Performance
In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.
Financial numbers in JPY Financial StatementsNews
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
Towa Pharmaceutical upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Jaeheon Lee upgraded Towa Pharmaceutical (TWAPF) to Overweight from Equal Weight with a price target of 5,600 yen, up from 4,500 yen, citing clearer earnings growth potential…